5 Key Takeaways

• 1

  Early selective laser trabeculoplasty (SLT) effectively controls intraocular pressure and reduces disease progression in open-angle glaucoma.

• 2

  The LiGHT trial included 718 treatment-naïve subjects and demonstrated SLT's advantages over medication in managing glaucoma.

• 3

  Patients in the SLT-first group achieved drop-free IOP control in nearly 70% of cases and required fewer surgeries than the medication-first group.

• 4

  Economic analysis favored SLT as a cost-effective treatment, reducing the financial burden on the UK's National Health Service.

• 5

  The trial results have led to a shift in glaucoma care practices, with SLT now recommended as a first-line treatment in the UK and the US.